neuroprotection And NotRobert A. Hauser
List of bibliographic references
Number of relevant bibliographic references: 36.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000229 | Yuen-Sum Lau [États-Unis] ; Gaurav Patki [États-Unis] ; Kaberi Das-Panja [États-Unis] ; Wei-Dong Le [États-Unis] ; S. Omar Ahmad [États-Unis] | Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson’s disease with moderate neurodegeneration |
| 000318 | Peter Jenner [Royaume-Uni] ; J. William Langston [États-Unis] | Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline |
| 000370 | A. H. V. Schapira [Royaume-Uni] | Challenges to the development of disease‐modifying therapies in Parkinson’s disease |
| 000379 | Robert D. Altman [Canada] ; Anthony E. Lang [Canada] ; Ronald B. Postuma [Canada] | Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study |
| 000416 | Anthony E. Lang [Canada] | A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials |
| 000567 | Anthony H. V. Schapira [Royaume-Uni] ; Stefan Albrecht [Allemagne] ; Paolo Barone [Italie] ; Cynthia L. Comella [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Kenneth Marek [États-Unis] | Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study |
| 000630 | Xiao-Qing Tang [République populaire de Chine] ; Yu-Juan Li ; Jing Zhao ; Xing-Tian Shen ; Chun-Tao Yang ; Li-Li Fan ; Bi Hu ; Yuan-Jian Li ; Duan-Fan Liao [République populaire de Chine] | Neuroprotective effect of asymmetric dimethylarginine against 1‐methyl‐4‐phenylpyridinium ion‐induced damage in PC12 cells |
| 000731 | Noriyuki Yamamoto [Japon] ; Yasuhiko Izumi [Japon] ; Takaaki Matsuo [Japon] ; Seiko Wakita [Japon] ; Toshiaki Kume [Japon] ; Yuki Takada-Takatori [Japon] ; Hideyuki Sawada [Japon] ; Akinori Akaike [Japon] | Elevation of heme oxygenase‐1 by proteasome inhibition affords dopaminergic neuroprotection |
| 000841 | Barry J. Snow [Nouvelle-Zélande] ; Fiona L. Rolfe [Nouvelle-Zélande] ; Michelle M. Lockhart [Nouvelle-Zélande] ; Christopher M. Frampton [Nouvelle-Zélande] ; John D. O'Sullivan [Australie] ; Victor Fung [Australie] ; Robin A. J. Smith [Nouvelle-Zélande] ; Michael P. Murphy [Royaume-Uni] ; Kenneth M. Taylor [Nouvelle-Zélande] | A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease |
| 000994 | A. H. Schapira [Royaume-Uni] ; Yves Agid [France] ; P. Barone [Italie] ; P. Jenner [Royaume-Uni] ; M. R. Lemke [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; H. Reichmann [Allemagne] ; E. Tolosa [Espagne] | Perspectives on recent advances in the understanding and treatment of Parkinson’s disease |
| 000A14 | Hiroki Takeuchi [Japon] ; Takashi Yanagida [Japon] ; Masatoshi Inden [Japon] ; Kazuyuki Takata [Japon] ; Yoshihisa Kitamura [Japon] ; Kentaro Yamakawa [Japon] ; Hideyuki Sawada [Japon] ; Yasuhiko Izumi [Japon] ; Noriyuki Yamamoto [Japon] ; Takeshi Kihara [Japon] ; Kengo Uemura [Japon] ; Haruhisa Inoue [Japon] ; Takashi Taniguchi [Japon] ; Akinori Akaike [Japon] ; Ryosuke Takahashi [Japon] ; Shun Shimohama [Japon] | Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone‐induced Parkinson's disease models |
| 000A19 | Robert G. Hart [États-Unis] ; Lesly A. Pearce [États-Unis] ; Bernard M. Ravina [États-Unis] ; Toby C. Yaltho [États-Unis] ; John R. Marler [États-Unis] | Neuroprotection trials in Parkinson's disease: Systematic review |
| 000A73 | Na K. Kim [Corée du Sud] ; Byung H. Choi [Corée du Sud] ; Xian Huang [Corée du Sud] ; Brian J. Snyder [Canada] ; Shefqat Bukhari [Canada] ; Tae-Ho Kong [Corée du Sud] ; Hyeonseon Park [Corée du Sud] ; Hyung C. Park [Corée du Sud] ; So R. Park [Corée du Sud] ; Yoon Ha [Corée du Sud] | Granulocyte–macrophage colony‐stimulating factor promotes survival of dopaminergic neurons in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced murine Parkinson’s disease model |
| 000C29 | Ilana Schlesinger [Israël] ; Naomi Schlesinger [États-Unis] | Uric acid in Parkinson's disease |
| 000C50 | Anthony H. V. Schapira [Royaume-Uni] | The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease |
| 000C79 | Genevieve Bureau [Canada] ; Fanny Longpré [Canada] ; M. Martinoli [Canada] | Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation |
| 000C96 | A. H. V. Schapira [Royaume-Uni] | Progress in neuroprotection in Parkinson’s disease |
| 000D31 | Maryka Quik [États-Unis] ; Kathryn O'Leary [États-Unis] ; Caroline M. Tanner [États-Unis] | Nicotine and Parkinson's disease: Implications for therapy |
| 000E64 | Carl E. Clarke [Royaume-Uni] | Are delayed‐start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? |
| 001003 | Julie Deguil [France] ; David Jailloux [France] ; Guylène Page [France] ; Bernard Fauconneau [France] ; Jean-Luc Houeto [France] ; Michel Philippe [France] ; Jean-Marc Muller [France] ; Stéphanie Pain [France] | Neuroprotective effects of pituitary adenylate cyclase–activating polypeptide (PACAP) in MPP+‐induced alteration of translational control in Neuro‐2a neuroblastoma cells |
| 001008 | Fernandez [États-Unis] ; Chen [États-Unis] | Monoamine Oxidase‐B Inhibition in the Treatment of Parkinson's Disease |
| 001050 | Anthony H. V. Schapira [Royaume-Uni] | Future directions in the treatment of Parkinson's disease |
| 001416 | Pedro Barroso-Chinea [Espagne] ; Ignacio Cruz-Muros [Espagne] ; María S. Aymerich [Espagne] ; Manuel Rodríguez-Díaz [Espagne] ; Domingo Afonso-Oramas [Espagne] ; José L. Lanciego [Espagne] ; Tomás González-Hernández [Espagne] | Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells |
| 001453 | Orly Weinreb [Israël] ; Tamar Amit [Israël] ; Orit Bar-Am [Israël] ; Orly Chillag-Talmor [Israël] ; Moussa B. H. Youdim [Israël] | Novel Neuroprotective Mechanism of Action of Rasagiline Is Associated with Its Propargyl Moiety: Interaction of Bcl‐2 Family Members with PKC Pathway |
| 001523 | Chen [États-Unis] ; Swope [États-Unis] | Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease |
| 001599 | Bala V. Manyam [États-Unis] ; Muralikrishnan Dhanasekaran [États-Unis] ; Theodore A. Hare [États-Unis] | Neuroprotective effects of the antiparkinson drug Mucuna pruriens |
| 001616 | Moussa B. H. Youdim [Israël] ; Galia Stephenson [Israël] ; Dorit Ben Shachar [Israël] | Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28 |
| 001667 | V. Anantharam [États-Unis] ; M. Kitazawa [États-Unis] ; C. Latchoumycandane [États-Unis] ; A. Kanthasamy [États-Unis] ; A G Kanthasamy [États-Unis] | Blockade of PKCδ Proteolytic Activation by Loss of Function Mutants Rescues Mesencephalic Dopaminergic Neurons from Methylcyclopentadienyl Manganese Tricarbonyl (MMT)‐Induced Apoptotic Cell Death |
| 001673 | Carl E. Clarke [Royaume-Uni] | A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs? |
| 001756 | Paul K. Morrish [Royaume-Uni] | How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? |
| 001881 | Nicole A. Abramova [États-Unis] ; David S. Cassarino [États-Unis] ; Shaharyar M. Khan [États-Unis] ; Terry W. Painter [États-Unis] ; James P. Bennett Jr. [États-Unis] | Inhibition by R(+) or S(–) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH‐SY5Y neuroblastoma |
| 001906 | A. H. V. Schapira | Dopamine agonists and neuroprotection in Parkinson's disease |
| 001908 | K. Marek [États-Unis] ; D. Jennings [États-Unis] ; J. Seibyl [États-Unis] | Do dopamine agonists or levodopa modify Parkinson's disease progression? |
| 001C49 | C. Scherfler [Autriche] ; Z. Puschban [Autriche] ; I. Ghorayeb [France] ; G. P Goebel [Autriche] ; F. Tison [France] ; K. Jellinger [Autriche] ; Werner Poewe [Autriche] ; G. K Wenning [Autriche] | Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy) |
| 001F19 | P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; K. Hyland [États-Unis] ; L. A. Arnold [États-Unis] ; K. D. Pettigrew [États-Unis] ; T. N. Chase [États-Unis] | Chronic Exposure to MPTP as a Primate Model of Progressive Parkinsonism: A Pilot Study with a Free Radical Scavenger |
| 002136 | Brigitte Piallat [France] ; Abdelhamid Benazzouz [France] ; Alim-Louis Benabid [France] | Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies |
| This area was generated with Dilib version V0.6.23. |  |